On this page
Manufacturing accounting is where the income statement meets the shop floor. Margin depends on what absorbed into inventory, revenue timing depends on shipping terms and acceptance clauses, and the balance sheet carries reserves (excess and obsolescence, warranty, purchase commitments) that are pure estimation.
We work with manufacturers across the spectrum, including capital equipment makers whose contracts bundle systems, installation, and service. The issues below are the recurring technical areas, each with the treatment we document and defend.
Issue 01
Equipment revenue: shipment, installation, and acceptance clausesASC 606
Capital equipment contracts bundle the system, installation, training, and warranty, and they almost always include customer acceptance testing. The recurring question: does revenue wait for the signed acceptance certificate, or does control transfer at shipment or delivery?
The treatmentIdentify the performance obligations first: the system and installation are separate obligations when the customer could benefit from the equipment with readily available installation resources; highly specialized integration can make them one combined obligation. For acceptance clauses, the answer turns on substance: if the entity can objectively demonstrate the equipment meets the agreed specifications before acceptance (standard products, factory test protocols mirroring the acceptance criteria), acceptance is a formality and control transfers at shipment or delivery per the shipping terms. If acceptance involves subjective criteria, novel configurations, or performance in the customer’s unique environment that cannot be replicated in advance, revenue waits for acceptance. Allocate the transaction price on standalone selling prices, defer the service and extended warranty elements, and document the acceptance analysis product line by product line, because the SEC comments on exactly this in capital equipment filings.
What we do: We write the acceptance-clause revenue memo product line by product line, which is exactly what the SEC comments on in capital equipment filings.
From our engagements: For semiconductor capital equipment fact patterns, the position usually lands on objective factory-test evidence for mature tools and acceptance-based recognition for first-in-fab configurations. The product-line memo is what makes that defensible.
Issue 02
Standard costing, variances, and absorptionASC 330
Most manufacturers run standard costs in the ERP, but GAAP inventory must approximate actual cost under full absorption. Purchase price, labor, and overhead variances accumulate all year, and the treatment of idle capacity is a rule people misquote.
The treatmentStandards are acceptable when variances are allocated between inventory and cost of sales so ending inventory approximates actual cost; expensing all favorable-and-unfavorable variances as incurred is only right when they are insignificant. Fixed production overhead is allocated based on normal capacity: in periods of abnormally low production, the unallocated fixed overhead is expensed in the period incurred, not loaded into fewer units, and abnormal freight, handling, and spoilage are period costs too. Refresh standards at least annually, document the normal-capacity basis, and keep the variance capitalization model as a standing close schedule so the year-end true-up is a rollforward, not a project.
What we do: We build the variance capitalization model as a standing close schedule, so the year-end true-up is a rollforward instead of a project.
Issue 03
Excess and obsolescence: the reserve that moves marginASC 330
Demand forecasts miss, designs change, and inventory built for last year’s roadmap ages on the shelf. The E&O reserve is where those misses land, and because it is formula-plus-judgment, it is a favorite target for both auditors and earnings management questions.
The treatmentBuild the reserve on a documented, consistently applied methodology: demand coverage analysis comparing on-hand and on-order quantities to forecast horizons, aging and last-usage screens, and specific identification for end-of-life and engineering-change exposure, with lower of cost and net realizable value applied on top for items selling below cost. Two rules keep it defensible: write-downs establish a new cost basis and are not reversed when demand recovers, and reserved inventory later sold should be tracked, because a pattern of selling through reserves signals the model over-reserves. Firm, noncancelable purchase commitments for excess quantities take a loss accrual when the commitment itself is underwater. Keep the methodology stable across periods; changing the formula in a soft quarter is the finding.
What we do: We document the excess-and-obsolescence methodology and keep it stable across periods, so the reserve holds up and does not read as earnings management.
Working through one of these in your own books? Talk to us before your audit.
Talk to an Expert
Issue 04
Warranties: assurance accrual or deferred revenueASC 460 / 606
Every product ships with a warranty, and many manufacturers also sell extended coverage. The two look similar in the contract and account completely differently.
The treatmentAssurance-type warranties, promising the product works as specified, are not performance obligations: accrue the expected cost of claims at the time of sale under ASC 460, built on claims-rate history by product family, cost per claim, and specific accruals for known defects or recalls, with a rollforward disclosed. Service-type warranties, extended terms or coverage beyond assurance (or any warranty the customer can buy separately), are performance obligations: allocate transaction price to them and recognize revenue over the coverage period. Contracts that bundle a long stated warranty need the split analysis: the portion beyond standard assurance is deferred revenue. New product launches without claims history borrow rates from the closest analog and true up quickly, with the estimation risk disclosed.
What we do: We split assurance from service warranties, build the claims accrual, and set the deferred revenue, with the rollforward your disclosures require.
Issue 05
Capital intensity: long-lived assets and goodwill in the cycleASC 360 / 350
Manufacturers carry heavy fixed asset bases and, after acquisitions, goodwill, into demand cycles they do not control. Downturns, capacity rationalizations, and plant consolidations all trigger impairment mechanics, in a required order.
The treatmentSequence matters: test in the order indefinite-lived intangibles, then long-lived assets and finite intangibles, then goodwill. Long-lived assets group at the lowest level of largely independent cash flows, often a plant or product line; on a trigger (sustained losses, decision to exit, market deterioration), run the undiscounted cash flow recoverability test over the primary asset’s remaining life, and only if it fails, measure impairment to fair value. Assets held for sale move to that classification at lower of carrying amount and fair value less cost to sell, with depreciation stopped. Goodwill tests annually and on triggers at the reporting unit, a single-step comparison of carrying amount to fair value. Idle capacity, meanwhile, hits the income statement through the normal-capacity rule rather than waiting for impairment. Document asset groupings and reporting units before the downturn; defining them during one invites scrutiny.
What we do: We define the asset groups and reporting units before the cycle turns and run the impairment testing in the required order when a trigger hits.
Issue 06
Supply chain: commitments, prepayments, tariffs, and hedgesASC 330 / 815
Securing capacity means signing take-or-pay supply agreements, prepaying strategic vendors, absorbing tariffs into landed cost, and sometimes hedging metals or currencies. Each has a specific home in the books.
The treatmentFirm purchase commitment losses are accrued when noncancelable commitments exceed market or expected recoverable value, with material commitments disclosed either way. Vendor prepayments and capacity deposits are assets assessed for recoverability against the supplier’s ability to deliver. Tariffs and duties are product costs, capitalized into inventory and released through cost of sales, not expensed as incurred, which moves margin timing when rates change. Commodity and FX hedges qualify for hedge accounting only with contemporaneous designation and documentation at inception; undesignated economic hedges mark to market through earnings, creating the volatility hedge accounting exists to fix. Physical supply contracts with fixed pricing also get the derivative screen, with normal purchases, normal sales documented where elected.
What we do: We set the accounting for commitments, prepayments, tariffs, and hedges, and document hedge designations at inception so the accounting actually qualifies.
Issue 07
Government incentives: credits, grants, and no US GAAP standardASC 740 / IAS 20
Semiconductor and advanced manufacturing incentives (investment credits, direct grants, state packages) arrived faster than US GAAP guidance for them. Business entities have no dedicated grant standard, so policy elections carry the weight.
The treatmentSort each incentive first: amounts governed by the tax law’s mechanics that depend on taxable income run through ASC 740; refundable or transferable credits and direct grants that do not depend on taxable income are outside it. For those, US GAAP business entities analogize, most commonly to IAS 20: recognize when there is reasonable assurance of compliance with conditions and receipt, and present asset-related grants as a reduction of the asset’s basis (or deferred income amortized over its life) and income-related grants in earnings as the related costs are incurred. Disclose the policy, the amounts, and the unmet conditions, and track clawback provisions as contingencies. Milestone-based disbursements should be recognized on the compliance pattern, not the cash pattern.
What we do: We sort each incentive, set the recognition policy, and draft the disclosures, including the clawback conditions, so the treatment is defensible.